ImmunoGen, Inc. Announces Vice President Promotions in Product Development
June 22 2010 - 2:02PM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that
develops targeted anticancer therapeutics, today announced the
promotion to vice president of two executive directors – Godfrey
Amphlett, Ph.D., and Robert J. Lutz, Ph.D. – who have played
central roles in establishing ImmunoGen’s highly successful product
development capabilities. These functions complement the Company’s
strong research capabilities in ImmunoGen’s advancement of its own
novel anticancer compounds and the industry-leading
target-to-commercial product expertise the Company provides to its
partners.
“Over the past few years, Bob and Godfrey have led the
transformation of functions that enable us to successfully build
and advance our proprietary product pipeline as well as provide
industry-leading support to our partners,” commented Daniel Junius,
President and Chief Executive Officer. “ImmunoGen has transitioned
from being an organization with strong research to one with equally
productive – and unique – development capabilities.”
Godfrey Amphlett, Ph.D., Vice President, Process and
Analytical Development
Since joining ImmunoGen in 2001, Dr. Amphlett has built a team
with industry-leading expertise in the many areas critical to
transforming a promising research compound into a
commercially-manufacturable, approvable product. These include
process development, formulation development, characterization and
analytical methods for both the individual product components as
well as for the complete drug product. For example, his team
developed the commercial-scale production processes for
trastuzumab-DM1 (T-DM1) and SAR3419 for Genentech and
sanofi-aventis, respectively.
Prior to joining ImmunoGen in 2001, Dr. Amphlett held positions
of increasing responsibility at Genetics Institute, now a part of
Pfizer, and at Armour Pharmaceuticals, a subsidiary of Revlon
Health Care. He earned a B.A. from the University of Cambridge,
England, and a Ph.D. from the University of Birmingham, England.
Dr. Amphlett did his postdoctoral work at the University of Notre
Dame, South Bend, IN.
Robert J. Lutz, Ph.D., Vice President, Translational Research
and Development
Dr. Lutz has held positions of increasing responsibility since
joining ImmunoGen as a Scientist in 1992. He gained broad
responsibility for ImmunoGen’s preclinical development functions
with his promotion to Senior Director of Preclinical Development in
2004 and to Executive Director, Preclinical Development in 2007. In
early 2010, he gained added responsibility for project management,
becoming Executive Director, Drug Development.
Dr. Lutz leads functions that provide support essential to the
successful advancement of ImmunoGen and partner new product
candidates from research through clinical development and the
leveraging of findings in the clinic to further enhance ImmunoGen’s
proprietary product pipeline. He earned a B.S. from the University
of New Hampshire, NH, and a Ph.D. from Brandeis University, MA. Dr.
Lutz did his postdoctoral work at the Eleanor Roosevelt Institute
for Cancer Research, Denver, CO.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using
its expertise in cancer biology, monoclonal antibodies and the
creation and attachment of potent cancer-cell killing agents. The
Company’s Targeted Antibody Payload (TAP) technology uses
antibodies to deliver one of ImmunoGen’s highly potent cancer-cell
killing agents specifically to tumors. In addition to the Company’s
product pipeline, compounds utilizing the TAP technology are in
clinical testing through ImmunoGen’s collaborations with Genentech
(a wholly owned member of the Roche Group), sanofi-aventis, Biogen
Idec and Biotest. The most advanced compound, T-DM1, is in
Phase III testing being conducted by Genentech and Roche.
Other ImmunoGen collaborative partners include Bayer Schering
Pharma and Amgen. More information about ImmunoGen can be found at
www.immunogen.com.
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2023 to Jul 2024